# Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00422604** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 60 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** salmeterol
- **DRUG:** tiotropium
- **DRUG:** GSK233705

## Key facts

- **NCT ID:** NCT00422604
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422604, "Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00422604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*